Everest Medicines Limited

DB:6HN Stock Report

Market Cap: €1.5b

Everest Medicines Valuation

Is 6HN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6HN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6HN (€4.4) is trading above our estimate of fair value (€3.84)

Significantly Below Fair Value: 6HN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6HN?

Key metric: As 6HN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6HN. This is calculated by dividing 6HN's market cap by their current revenue.
What is 6HN's PS Ratio?
PS Ratio27x
SalesCN¥418.55m
Market CapCN¥11.28b

Price to Sales Ratio vs Peers

How does 6HN's PS Ratio compare to its peers?

The above table shows the PS ratio for 6HN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.9x
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
14x33.4%€827.2m
2INV 2invest
8.1xn/a€63.8m
HPHA Heidelberg Pharma
12x16.6%€103.9m
6HN Everest Medicines
27x37.2%€12.1b

Price-To-Sales vs Peers: 6HN is expensive based on its Price-To-Sales Ratio (27x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does 6HN's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
6HN 27.0xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6HN is expensive based on its Price-To-Sales Ratio (27x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 6HN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6HN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio27x
Fair PS Ratio9.4x

Price-To-Sales vs Fair Ratio: 6HN is expensive based on its Price-To-Sales Ratio (27x) compared to the estimated Fair Price-To-Sales Ratio (9.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6HN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.40
€3.03
-31.2%
6.9%€3.46€2.84n/a6
Nov ’25€3.56
€3.03
-15.0%
6.9%€3.46€2.84n/a6
Oct ’25€2.98
€3.03
+1.5%
6.9%€3.46€2.84n/a6
Sep ’25€2.34
€3.03
+29.3%
7.5%€3.50€2.82n/a6
Aug ’25€2.20
€3.08
+39.9%
7.6%€3.52€2.84n/a6
Jul ’25€2.22
€3.31
+49.3%
18.3%€4.70€2.83n/a7
Jun ’25€2.52
€3.31
+31.5%
18.3%€4.70€2.83n/a7
May ’25€2.80
€3.34
+19.2%
18.5%€4.75€2.86n/a7
Apr ’25€2.70
€3.34
+23.6%
18.5%€4.75€2.86n/a7
Mar ’25€2.74
€3.12
+13.8%
22.6%€4.76€2.51n/a7
Feb ’25€1.82
€3.10
+70.4%
22.3%€4.72€2.49n/a7
Jan ’25€2.30
€3.16
+37.2%
23.0%€4.77€2.21n/a7
Dec ’24€2.26
€3.12
+38.2%
22.9%€4.71€2.18n/a7
Nov ’24€3.48
€2.70
-22.5%
13.1%€3.09€2.21€3.566
Oct ’24€2.90
€2.70
-7.0%
13.1%€3.09€2.21€2.986
Sep ’24€2.04
€2.66
+30.6%
14.7%€3.40€2.13€2.347
Aug ’24€2.44
€2.55
+4.5%
21.4%€3.37€1.78€2.207
Jul ’24€2.76
€2.54
-7.8%
22.0%€3.38€1.78€2.227
Jun ’24€1.25
€2.61
+109.1%
21.1%€3.36€1.85€2.527
May ’24€1.60
€2.82
+76.2%
25.0%€4.08€1.87€2.808
Apr ’24€1.73
€2.90
+67.9%
22.6%€4.06€2.01€2.708
Mar ’24€2.08
€2.97
+42.6%
22.3%€4.14€1.88€2.749
Feb ’24€2.87
€2.89
+0.6%
23.3%€4.09€1.67€1.829
Jan ’24€1.99
€2.79
+40.3%
28.9%€4.11€1.65€2.309
Dec ’23€1.33
€2.78
+109.6%
29.1%€4.09€1.64€2.269
Nov ’23€0.83
€2.94
+255.0%
29.4%€4.31€1.73€3.489

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$707.40

7D

-0.9%

1Y

-3.6%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

1.3%

1Y

89.7%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%